Prostaglandin D2 metabolite is not a useful clinical indicator for assessing atopic dermatitis.

Like Comment
Prostaglandin D2 (PGD2 ) plays an important role in atopic dermatitis (AD) and 11, 15-dioxo-9α-hydroxy-, 2, 3, 4, 5-tetranorprostan-1, 20-dioicacid (PGDM) is a major metabolite of PGD2 . We investigated the relationship between the urinary-PGDM levels and the severity of pediatric AD. Thirty-one AD and 21 non-AD subjects were recruited, and urinary-PGDM levels were measured. 14 AD patients were assessed for urinary-PGDM after topical steroid therapy. There was no difference in urinary-PGDM levels between the AD patients and healthy subjects. Although there was a significant positive correlation between the SCORing of AD (SCORAD) index and the serum level of thymus and activation-regulated chemokine (TARC), the urinary-PGDM levels were not correlated with SCORAD and serum TARC. Moreover, SCORAD and serum TARC were significantly improved by topical steroid therapy; however, urinary-PGDM levels were not changed. The level of urinary PGD2 metabolites in AD children is substantially equal to that in heathy controls even if the disease is severe.

Get PDF with LibKey

View the article @ Clinical and experimental dermatology (sign-in may be required)


The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
6577 Contributions
0 Following